Ovarian dysfunction associated with an anticonvulsant drug.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000311:Adrenal Glands / Q000187:drug effects; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000814:Aniline Compounds / Q000009:adverse effects*; D000927:Anticonvulsants / Q000009:adverse effects*; D004700:Endocrine System Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D006984:Hypertrophy; D008797:Metyrapone; D010053:Ovary / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D010912:Pituitary-Adrenal Function Tests; D011728:Pyridones / Q000009:adverse effects*; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000187:drug effects; D014770:Virilism / Q000139:chemically induced*
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000814:Aniline Compounds; D000927:Anticonvulsants; D011728:Pyridones; D000616:Aminoglutethimide; D000324:Adrenocorticotropic Hormone; D008797:Metyrapone